<DOC>
	<DOCNO>NCT01854476</DOCNO>
	<brief_summary>Patients chronic treatment hemodialysis arterio-venous fistula enable insertion two large gauge needle . At end dialysis needle extract continuous pressure need stop bleeding . Time bleed cessation different patient may 20 minute . Acquired coagulopathy patient chronic hemodylasis well know entity . The coagulopathy multi-factorial include uremic thrombocytopathia , presence anemia , use anti-platelets and/or anti-coagulation drug regular use heparin dialysis . Tranexamic acid ( Hexakapron ) anti-fibrinolytic drug prove efficacy reduce blood loss different clinical setting . The drug may give systemically ( PO/IV ) apply locally site injury . The aim study assess efficacy safety pad gauze dress contain tranexamic acid . Study design : A Double-blind study compare pad-gauze tranexamic acid ( Hemostopan™ ) regular pad-gauze . The type dress dialysis session decide random manner . In dialysis session one type dressing use insertion point . Protocol apply dressing : Following needle extraction either dress `` A '' `` B '' apply slight pressure 2 minute . If bleed stops end session . If bleeding persists another dress kind apply slight pressure 4 minute . If bleed stops end session . If bleeding persists another dress kind apply slight pressure 6 minute . If bleed stops end session . If bleeding persists consider failure regular measure use bleed stop . Each session document patient 's case report file ( CRF ) . The primary end point study : Time bleed cessation</brief_summary>
	<brief_title>Safety Efficacy Study Comparing Pad-gauze With Anti-fibrinolytic Agent Hemostopan™ ) Regular Pad-gauze</brief_title>
	<detailed_description>A Double-blind safety efficacy study compare pad-gauze tranexamic acid ( Hemostopan™ ) regular pad-gauze control bleeding patient hemodialysis . Background : Patients end-stage renal disease chronic treatment hemodialysis . Most patient arterio-venous fistula enable insertion two large gauge needle . At end dialysis needle extract continuous pressure need stop bleeding . Time hemostasis different patient may 20 minute insertion point . Acquired coagulopathy patient chronic hemodylasis well know entity important impact time hemostasis . The coagulopathy multi-factorial compose include uremic thrombocytopathia , presence anemia , use anti-platelets / anti-coagulation drug regular use heparin dialysis process . Tranexamic acid ( Hexakapron ) anti-fibrinolytic drug prove efficacy reduce blood loss different clinical setting . The drug may give systemically ( PO / IV ) apply locally site injury . The aim study To study efficacy safety pad gauze dress contain tranexamic acid . Inclusion criterion : Patients require least 10 minute hemostasis consider candidate study . Among , patient 18 year age sign inform consent recruit . Exclusion criterion : Patients HIV , HCV HBV chronic infection . Known hypersensitivity polydine . Study design : A Double-blind study compare pad-gauze tranexamic acid ( Hemostopan™ ) regular pad-gauze . The type dress dialysis session decide random manner . In dialysis session one type dressing use insertion point . The dress identical appearance mark dress `` A '' dress `` B '' . All participant include - patient , physician , nurse study coordinator blind treatment . In ta course study dress apply 10 time give patient practical patient control . Protocol apply dressing : Following needle extraction either dress `` A '' `` B '' apply slight pressure 2 minute . If bleed stops end session . If bleeding persists another dress kind apply slight pressure 4 minute . If bleed stops end session . If bleeding persists another dress kind apply slight pressure 6 minute . If bleed stops end session . If bleeding persists consider failure regular measure use bleed stop . Each session document patient 's case report file ( CRF ) . The primary end point study : Time hemostasis</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<mesh_term>Antifibrinolytic Agents</mesh_term>
	<criteria>Patients require least 10 minute hemostasis Patient 18 year age capable signing informed consent Patients HIV , HCV HBV chronic infection Known hypersensitivity polydine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>Bleeding</keyword>
	<keyword>Hemostatic dressing</keyword>
	<keyword>Tranexamic Acid</keyword>
</DOC>